
Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal
Sanofi is acquiring Blueprint Medicines for $9.1 billion to strengthen its rare immunology portfolio, marking the largest biopharma deal since January.
All articles tagged with #blueprint medicines

Sanofi is acquiring Blueprint Medicines for $9.1 billion to strengthen its rare immunology portfolio, marking the largest biopharma deal since January.